Ye, H., Li, Z., Liu, K., Zhang, F., & Cheng, Z. (2021). Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety. Medicine (Baltimore).
Chicago Style CitationYe, Haiyong, Zhaoyi Li, Kangning Liu, Feng Zhang, i Zhengliang Cheng. "Anlotinib, a Novel TKI, As a Third-line or Further-line Treatment in Patients With Advanced Non-small Cell Lung Cancer in China: A Systemic Review and Meta-analysis of Its Efficacy and Safety." Medicine (Baltimore) 2021.
Cita MLAYe, Haiyong, et al. "Anlotinib, a Novel TKI, As a Third-line or Further-line Treatment in Patients With Advanced Non-small Cell Lung Cancer in China: A Systemic Review and Meta-analysis of Its Efficacy and Safety." Medicine (Baltimore) 2021.